29 January 2025 - Initiated rolling new drug application submission, now to include long-term extension data given continued clinical improvement over time, with submission completion expected in Q3, 2025.

Ironwood Pharmaceuticals today announced a streamlined strategic focus on advancing and realising the potential of apraglutide for the treatment of short bowel syndrome patients who are dependent on parenteral support.

Read Ironwood Pharmaceuticals press release